Associations and outcomes of patients with submacular haemorrhage secondary to age-related macular degeneration in the IVAN trial

Alexander Mehta , David Steele*, Alyson Muldrew, Tunde Peto, Barnaby C Reeves, Rebecca N Evans, Usha Chakravarthy

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

Abstract

Purpose: To compare demographics, visual acuity (VA) and retinal morphology between those with and without baseline submacular haemorrhage (SMH) for patients enrolled in the Inhibit VEGF in Age-related Choroidal Neovascularisation trial (IVAN).
Design: Secondary analyses of RCT image and clinical data.
Methods
Setting: Clinical trial data collected in 23 UK hospitals.
Study Population: IVAN study eyes (with untreated neovascular age-related macular degeneration (nAMD) at randomisation) with at least 12 months’ follow-up and adequate imaging.
Intervention: Study eyes randomly assigned between monthly ranibizumab, as-needed
ranibizumab, monthly bevacizumab or as-needed bevacizumab. Imaging at baseline graded independently for presence, type, position and extent of SMH.
Main Outcome Measures: Visual acuity (primary outcome), subretinal fibrosis, atrophic scarring and retinal thickness outcomes at 12 and 24 months
Results: 535 of 605 IVAN trial participants were included. Patients with SMH at baseline (286, 53%) were older (p=0.010), and affected eyes were more likely to have intraretinal fluid present (p=0.038). VA was significantly worse in those with baseline SMH at month 0 (p<0.001; estimate of difference 6 letters with 95% confidence intervals of 4 to 8 letters) but the difference decreased and was not significant at month 12 or 24. No significant association was found between baseline SMH and subretinal fibrosis, atrophic scarring or central retinal thickness.
Conclusion: Presence of SMH at baseline was associated with age, intraretinal fluid and reduced baseline VA. By month 12, VA was no longer significantly different in those who presented with SMH at baseline.
Original languageEnglish
JournalAmerican Journal of Ophthalmology
Publication statusAccepted/In press - 29 Sep 2021

Keywords

  • Submacular haemorrhage
  • neovascular age-related macular degeneration
  • colour fundus photographs
  • visual outcomes
  • risk factors
  • anti VEGF
  • intravitreal injection

Fingerprint

Dive into the research topics of 'Associations and outcomes of patients with submacular haemorrhage secondary to age-related macular degeneration in the IVAN trial'. Together they form a unique fingerprint.

Cite this